StockNews.AISignal intelligence
Doximity, Inc. · NYSE · Healthcare
Browse public DOCS signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Doximity reported Q1 results with an earnings miss but raised full-year revenue guidance, highlighting stronger AI-driven engagement. Analysts turned more bullish on improving growth momentum and the potential for AI products to boost future monetization, suggesting the stock could re-rate higher in the near term.
View signal analysisDoximity delivered a mixed Q4 with soft full-year guidance as the HCP digital pharma ad market faces policy and macro headwinds. Management guides modest growth at or below 5% this year, while Bank of America flags AI-pivot costs and pricing pressures, trimming the target to $20. The stock fell on the downgrade, underscoring near-term sentiment risk tied to AI investments.
View signal analysisDoximity's Q4 earnings missed expectations, prompting significant analyst downgrades and lower future revenue guidance. The stock is struggling at a new 52-week low, indicating ongoing challenges amidst soft advertising demand. Investors should be cautious as growth slows and sentiment weakens.
View signal analysisDoximity's upcoming earnings report on May 13 is expected to reveal weaker-than-last-year performance, with EPS projected to drop to $0.28. The resignation of CFO Anna Bryson raises leadership concerns, potentially impacting investor confidence and stock performance in the near term.
View signal analysisDoximity reported Q3 revenue of $185.05 million, surpassing analyst estimates, with a year-over-year growth of 10%. This performance suggests positive momentum in their business model, potentially impacting investor sentiment around DOCS in the near term.
View signal analysisDoximity reported Q1 earnings of 36 cents per share, beating estimates. Quarterly sales reached $145.913 million, surpassing analyst expectations. Doximity raised FY2026 sales guidance to between $628 and $636 million. The AI product suite grew 5x year-over-year, indicating strong demand. Analysts raised price targets, with Needham at $75 from $67.
View signal analysis